-
公开(公告)号：US20090054426A1
公开(公告)日：2009-02-26
申请号：US12195937
申请日：2008-08-21
申请人： R. Scott Bitner , Kaitlin E. Browman , Michael E. Brune , Yixian Chen , Jurgen Dinges , Karla Drescher , Peer Jacobson , Hwan-soo Jae , Ravi Kurukulasuriya , James T. Link , David J. Madar , Jyoti R. Patel , Marina A. Pliushchev , Jeffrey J. Rohde , Lynne E. Rueter , Qi Shuai , Bryan K. Sorensen , Jiahong Wang , Karsten M. Wicke , Martin Winn , Dariusz Wodka , Vince Yeh , Hong Yong
发明人： R. Scott Bitner , Kaitlin E. Browman , Michael E. Brune , Yixian Chen , Jurgen Dinges , Karla Drescher , Peer Jacobson , Hwan-soo Jae , Ravi Kurukulasuriya , James T. Link , David J. Madar , Jyoti R. Patel , Marina A. Pliushchev , Jeffrey J. Rohde , Lynne E. Rueter , Qi Shuai , Bryan K. Sorensen , Jiahong Wang , Karsten M. Wicke , Martin Winn , Dariusz Wodka , Vince Yeh , Hong Yong
IPC分类号： A61K31/496 , A61P25/00 , A61K31/5375 , A61K31/445 , A61K31/16
CPC分类号： C07D403/12 , A61K31/44 , A61K31/495 , C07D207/267 , C07D401/12 , C07D401/14
摘要： A method for treating a patient suffering from disorders and deficits of the central nervous system associated with diabetes, associated with aging and neurodegeneration, comprising attention deficit disorder in general, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment, senile dementia, AIDS dementia, neurodegeneration, depression, and schizophrenia, comprising administering to a patient in need of such treatment an effective amount of a selective inhibitor of the 11-β-hydroxysteroid dehydrogenase Type 1 enzyme activity.
摘要翻译： 一种治疗患有与老化和神经变性相关的糖尿病中枢神经系统紊乱和缺陷的患者的方法，包括注意力缺陷障碍，注意力缺陷多动障碍（ADHD），阿尔茨海默病（AD），轻度认知障碍 老年性痴呆，艾滋病痴呆，神经变性，抑郁和精神分裂症，包括向需要这种治疗的患者施用有效量的11-β-羟基类固醇脱氢酶1型酶活性的选择性抑制剂。
-
公开(公告)号：US20130059829A1
公开(公告)日：2013-03-07
申请号：US13554698
申请日：2012-07-20
申请人： R. Scott Bitner , Kaitlin E. Browman , Michael E. Brune , Yixian Chen , Jurgen Dinges , Karla Drescher , Peer Jacobson , Hwan-soo Jae , Ravi Kurukulasuriya , James T. Link , David J. Madar , Jyoti R. Patel , Marina A. Pliushchev , Jeffrey J. Rohde , Lynne E. Rueter , Qi Shuai , Bryan K. Sorensen , Jiahong Wang , Karsten M. Wicke , Martin Winn , Dariusz Wodka , Vince Yeh , Hong Yong
发明人： R. Scott Bitner , Kaitlin E. Browman , Michael E. Brune , Yixian Chen , Jurgen Dinges , Karla Drescher , Peer Jacobson , Hwan-soo Jae , Ravi Kurukulasuriya , James T. Link , David J. Madar , Jyoti R. Patel , Marina A. Pliushchev , Jeffrey J. Rohde , Lynne E. Rueter , Qi Shuai , Bryan K. Sorensen , Jiahong Wang , Karsten M. Wicke , Martin Winn , Dariusz Wodka , Vince Yeh , Hong Yong
IPC分类号： A61K31/5375 , A61K31/55 , A61K31/551 , A61K31/397 , A61K31/16 , A61P25/28 , A61P25/24 , A61P25/18 , A61P25/22 , A61K31/496 , A61P25/00
CPC分类号： C07D403/12 , A61K31/44 , A61K31/495 , C07D207/267 , C07D401/12 , C07D401/14
摘要： A method for treating a patient suffering from disorders and deficits of the central nervous system associated with diabetes, associated with aging and neurodegeneration, comprising attention deficit disorder in general, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment, senile dementia, AIDS dementia, neurodegeneration, depression, and schizophrenia, comprising administering to a patient in need of such treatment an effective amount of a selective inhibitor of the 11-β-hydroxysteroid dehydrogenase Type 1 enzyme activity.
-
公开(公告)号：US20100152179A9
公开(公告)日：2010-06-17
申请号：US12195937
申请日：2008-08-21
申请人： R. Scott Bitner , Kaitlin E. Browman , Michael E. Brune , Yixian Chen , Jurgen Dinges , Karla Drescher , Peer Jacobson , Hwan-soo Jae , Ravi Kurukulasuriya , James T. Link , David J. Madar , Jyoti R. Patel , Marina A. Pliushchev , Jeffrey J. Rohde , Lynne E. Rueter , Qi Shuai , Bryan K. Sorensen , Jiahong Wang , Karsten M. Wicke , Martin Winn , Dariusz Wodka , Vince Yeh , Hong Yong
发明人： R. Scott Bitner , Kaitlin E. Browman , Michael E. Brune , Yixian Chen , Jurgen Dinges , Karla Drescher , Peer Jacobson , Hwan-soo Jae , Ravi Kurukulasuriya , James T. Link , David J. Madar , Jyoti R. Patel , Marina A. Pliushchev , Jeffrey J. Rohde , Lynne E. Rueter , Qi Shuai , Bryan K. Sorensen , Jiahong Wang , Karsten M. Wicke , Martin Winn , Dariusz Wodka , Vince Yeh , Hong Yong
IPC分类号： A61K31/496 , A61P25/00 , A61K31/5375 , A61K31/445 , A61K31/16
CPC分类号： C07D403/12 , A61K31/44 , A61K31/495 , C07D207/267 , C07D401/12 , C07D401/14
摘要： A method for treating a patient suffering from disorders and deficits of the central nervous system associated with diabetes, associated with aging and neurodegeneration, comprising attention deficit disorder in general, attention deficit hyperactivity disorder (ADHD), Alzheimer's disease (AD), mild cognitive impairment, senile dementia, AIDS dementia, neurodegeneration, depression, and schizophrenia, comprising administering to a patient in need of such treatment an effective amount of a selective inhibitor of the 11-β-hydroxysteroid dehydrogenase Type 1 enzyme activity.
摘要翻译： 一种治疗患有与老化和神经变性相关的糖尿病中枢神经系统紊乱和缺陷的患者的方法，包括注意力缺陷障碍，注意力缺陷多动障碍（ADHD），阿尔茨海默病（AD），轻度认知障碍 老年性痴呆，艾滋病痴呆，神经退行性疾病，抑郁症和精神分裂症，包括向需要这种治疗的患者施用有效量的11-羟基类固醇脱氢酶1型酶活性的选择性抑制剂。
-
公开(公告)号：US08415354B2
公开(公告)日：2013-04-09
申请号：US12390329
申请日：2009-02-20
申请人： R. Scott Bitner , Kaitlin E. Browman , Michael E. Brune , Steven Fung , Peer B. Jacobson , Lynne E. Rueter , Marina I. Strakhova , Jiahong Wang , James T. Link , Yixian Chen , Hwan-soo Jae , Jyoti R. Patel , Marina A. Pliushchev , Jeffrey J. Rohde , Qi Shuai , Bryan K. Sorensen , Martin Winn , Dariusz Wodka , Hong Yong
发明人： R. Scott Bitner , Kaitlin E. Browman , Michael E. Brune , Steven Fung , Peer B. Jacobson , Lynne E. Rueter , Marina I. Strakhova , Jiahong Wang , James T. Link , Yixian Chen , Hwan-soo Jae , Jyoti R. Patel , Marina A. Pliushchev , Jeffrey J. Rohde , Qi Shuai , Bryan K. Sorensen , Martin Winn , Dariusz Wodka , Hong Yong
IPC分类号： A61K31/65 , A61K31/445 , A61K31/496 , C07C233/05 , C07D211/00 , C07D401/04
CPC分类号： C07D295/155 , A61K31/496 , A61K31/5375 , A61K31/55 , C07D205/04 , C07D207/12 , C07D209/44 , C07D211/42 , C07D213/72 , C07D231/12 , C07D239/42 , C07D277/82 , C07D295/125 , C07D307/68 , C07D401/04 , C07D401/12 , C07D413/12 , C07D487/04 , C07D491/056
摘要： The present invention relates to inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids.
-
15.发明申请METHODS OF USE OF INHIBITORS OF THE 11-BETA-HYDROXYSTEROID DEHYDROGENASE TYPE 1 ENZYME 有权11-羟基脱氢酶脱氢酶1型酶的抑制剂的使用方法公开(公告)号：US20090192141A1
公开(公告)日：2009-07-30
申请号：US12390329
申请日：2009-02-20
申请人： R. Scott Bitner , Kaitlin E. Browman , Michael E. Brune , Steven Fung , Peer B. Jacobson , Lynne E. Rueter , Marina I. Strakhova , Jiahong Wang , James T. Link , Yixian Chen , Hwan-soo Jae , Jyoti R. Patel , Marina A. Pliushchev , Jeffrey J. Rohde , Qi Shuai , Bryan K. Sorensen , Martin Winn , Dariusz Wodka , Hong Yong
发明人： R. Scott Bitner , Kaitlin E. Browman , Michael E. Brune , Steven Fung , Peer B. Jacobson , Lynne E. Rueter , Marina I. Strakhova , Jiahong Wang , James T. Link , Yixian Chen , Hwan-soo Jae , Jyoti R. Patel , Marina A. Pliushchev , Jeffrey J. Rohde , Qi Shuai , Bryan K. Sorensen , Martin Winn , Dariusz Wodka , Hong Yong
IPC分类号： A61K31/55 , C07D401/02 , A61K31/496 , A61K31/5375 , C07D295/00 , C07D223/16 , A61P25/24
CPC分类号： C07D295/155 , A61K31/496 , A61K31/5375 , A61K31/55 , C07D205/04 , C07D207/12 , C07D209/44 , C07D211/42 , C07D213/72 , C07D231/12 , C07D239/42 , C07D277/82 , C07D295/125 , C07D307/68 , C07D401/04 , C07D401/12 , C07D413/12 , C07D487/04 , C07D491/056
摘要： The present invention relates to inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids.
摘要翻译： 本发明涉及11-β-羟基类固醇脱氢酶1型酶的抑制剂及其在治疗非胰岛素依赖性2型糖尿病，胰岛素抵抗，肥胖，脂质障碍，代谢综合征，中枢神经系统疾病和疾病和病症中的用途 这与过量的糖皮质激素有关。
-
16.发明授权公开(公告)号：US07855308B2
公开(公告)日：2010-12-21
申请号：US12355909
申请日：2009-01-19
申请人： Michael E. Brune , Peer B. Jacobson , James T. Link , Jyoti R. Patel , Jeffrey J. Rohde , Qi Shuai , Martin Winn , Vince S. Yeh , Hong Yong
发明人： Michael E. Brune , Peer B. Jacobson , James T. Link , Jyoti R. Patel , Jeffrey J. Rohde , Qi Shuai , Martin Winn , Vince S. Yeh , Hong Yong
IPC分类号： C07C233/05 , A61K31/65
CPC分类号： C07C233/23 , C07C235/14 , C07C237/24 , C07C255/31 , C07C255/47 , C07C259/16 , C07C311/08 , C07C311/29 , C07C311/46 , C07C311/51 , C07C317/22 , C07C317/30 , C07C317/44 , C07C323/41 , C07C323/60 , C07C2601/04 , C07C2601/14 , C07C2601/18 , C07C2602/08 , C07C2602/10 , C07C2603/74 , C07D207/48 , C07D213/64 , C07D233/64 , C07D257/04 , C07D261/08
摘要： The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.
摘要翻译： 本发明涉及作为11-β-羟基类固醇脱氢酶1型酶抑制剂的化合物。 本发明还涉及11-β-羟基类固醇脱氢酶1型抑制剂用于治疗非胰岛素依赖性2型糖尿病，胰岛素抵抗，肥胖症，脂质障碍，代谢综合征和其他介导的疾病和病症的用途 由过度的糖皮质激素作用。
-
17.发明申请公开(公告)号：US20090131434A1
公开(公告)日：2009-05-21
申请号：US12355909
申请日：2009-01-19
申请人： Michael E. Brune , Peer B. Jacobson , James T. Link , Jyoti R. Patel , Jeffrey J. Rohde , Qi Shuai , Martin Winn , Vince S. Yeh , Hong Yong
发明人： Michael E. Brune , Peer B. Jacobson , James T. Link , Jyoti R. Patel , Jeffrey J. Rohde , Qi Shuai , Martin Winn , Vince S. Yeh , Hong Yong
IPC分类号： A61K31/5377 , C07C233/01 , C07D413/02 , A61P3/10 , A61K31/16
CPC分类号： C07C233/23 , C07C235/14 , C07C237/24 , C07C255/31 , C07C255/47 , C07C259/16 , C07C311/08 , C07C311/29 , C07C311/46 , C07C311/51 , C07C317/22 , C07C317/30 , C07C317/44 , C07C323/41 , C07C323/60 , C07C2601/04 , C07C2601/14 , C07C2601/18 , C07C2602/08 , C07C2602/10 , C07C2603/74 , C07D207/48 , C07D213/64 , C07D233/64 , C07D257/04 , C07D261/08
摘要： The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.
摘要翻译： 本发明涉及作为11-β-羟基类固醇脱氢酶1型酶抑制剂的化合物。 本发明还涉及11-β-羟基类固醇脱氢酶1型抑制剂用于治疗非胰岛素依赖性2型糖尿病，胰岛素抵抗，肥胖症，脂质障碍，代谢综合征和其他介导的疾病和病症的用途 由过度的糖皮质激素作用。
-
18.发明授权公开(公告)号：US07511175B2
公开(公告)日：2009-03-31
申请号：US11325965
申请日：2006-01-05
申请人： Jyoti R. Patel , Qi Shuai , James T. Link , Jeffrey J. Rohde , Jurgen Dinges , Bryan K. Sorensen , Martin Winn , Hong Yong , Peer B. Jacobson , Michael E. Brune
发明人： Jyoti R. Patel , Qi Shuai , James T. Link , Jeffrey J. Rohde , Jurgen Dinges , Bryan K. Sorensen , Martin Winn , Hong Yong , Peer B. Jacobson , Michael E. Brune
IPC分类号： C07C311/15 , A61K31/18
CPC分类号： C07C233/23 , C07C235/14 , C07C237/24 , C07C255/31 , C07C255/47 , C07C259/16 , C07C311/08 , C07C311/29 , C07C311/46 , C07C311/51 , C07C317/22 , C07C317/30 , C07C317/44 , C07C323/41 , C07C323/60 , C07C2601/04 , C07C2601/14 , C07C2601/18 , C07C2602/08 , C07C2602/10 , C07C2603/74 , C07D207/48 , C07D213/64 , C07D233/64 , C07D257/04 , C07D261/08
摘要： The present invention relates to compounds which are inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme. The present invention further relates to the use of inhibitors of 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme for the treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome and other diseases and conditions that are mediated by excessive glucocorticoid action.
摘要翻译： 本发明涉及作为11-β-羟基类固醇脱氢酶1型酶抑制剂的化合物。 本发明还涉及11-β-羟基类固醇脱氢酶1型抑制剂用于治疗非胰岛素依赖性2型糖尿病，胰岛素抵抗，肥胖症，脂质障碍，代谢综合征和其他介导的疾病和病症的用途 由过度的糖皮质激素作用。
-
19.发明授权Use of &agr;1A adrenoceptor agonists with &agr;1B and &agr;1D antagonism for the treatment of stress urinary incontinence 失效使用α1A肾上腺素能受体激动剂与α1B和α1D拮抗剂治疗压力性尿失禁公开(公告)号：US06323231B1
公开(公告)日：2001-11-27
申请号：US09788198
申请日：2001-02-16
IPC分类号： A61K31415
CPC分类号： A61K31/4174 , A61K31/00
摘要： The following disclosure relates to a method of treating incontinence with a compound having a specific &agr;1A adrenoceptor profile.
摘要翻译： 以下公开内容涉及用具有特定α1A肾上腺素受体概况的化合物治疗失禁的方法。
-
-
-
-
-
-
-
-
搜索结果
19 条记录 (耗时 0.039 秒)
